News | September 24, 2021
Novavax and Serum seek WHO approval for Covid-19 vaccine
It is a recombinant nanoparticle protein-based vaccine
It is a recombinant nanoparticle protein-based vaccine
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
This low-cost and highly reliable technology will help in increasing testing in rural and tribal areas
Research collaboration covers multiple antibody research programs
Subscribe To Our Newsletter & Stay Updated
